10.18.19
7 min. Read

Pear-Sandoz’s conscious uncoupling. W. Virgina wants DTx.

Issue 024.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 66 percent open rate, which, considering all the new enterprise subscribers, is A-OK by me. Here's what's happening this week:

  • The "bomb cyclone" of a Nor'Easter that hit the Boston-area Wednesday night slowed things down a little, but the only real casualty around here was one of the more promising branches I grafted to my apple tree this spring. Such are the trials and tribulations of backyard orcharding.
  • Fitbit continues its (probably quixotic) quest to transform its business into a behavior change company focused on helping people manage serious medical conditions before its low stock price gets it acquired. On-stage at Time's healthcare conference, CEO James Park announced a deal with the Bristol-Myers Squibb-Pfizer Alliance focused on atrial

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
PDT-to-virtual-clinic trend continues. HCPCS tweaks.
12.15.23
8 min. Read
Mahana Tinnitus. New CPT hopefuls. Better cuts salaries
12.01.23
6 min. Read
CMS weighs HCPCS for Natural Cycles, Leva, and Tyto. Plus: Akili Q3 results.
11.16.23
8 min. Read
metaMe Health seeks buyer by year-end. CMS offers up digital therapeutics nothingburger
11.06.23
6 min. Read
PDT Pipeline changes. Kinsa shuts down. Trials
10.27.23
5 min. Read
CPT decisions. Trials: Big Health, Mahana and more
10.20.23
6 min. Read
Akili CEO steps down. Aetna rolls back some virtual care coverage
10.06.23
5 min. Read
Biogen cuts digital, MedRhythms, Apple. Pfizer on PDTs.
9.29.23
6 min. Read
CMS: PDTs have potential. Trials: Big, Koko, GAIA
9.22.23
6 min. Read
Limbix acquisition price tag. Akili fully pivots to OTC.
9.15.23
6 min. Read
  • First
  • Previous
  • 1 of 20
  • Next
  • Last